| Drug Name: | Trazodone (19794-93-5) |
|---|---|
| PubChem ID: | 5533 |
| SMILES: | C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl |
| InchiKey: | PHLBKPHSAVXXEF-UHFFFAOYSA-N |
| Therapeutic Category: | Anti-Anxiety Agents, Antidepressive Agents, Central Nervous System Agents, Central Nervous System Depressants, Membrane Transport Modulators, Neurotransmitter Agents, Neurotransmitter Uptake Inhibitors, Psychotropic Drugs, Serotonin Agents, Serotonin Uptake Inhibitors, Tranquilizing Agents |
| Molecular Weight (dalton) | : | 371.872 |
| LogP | : | 2.3617 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 45.78 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Amiodarone (1951-25-3) | Torsade De Pointes | Additive | Not established | QT prolongation and polymorphous ventricular tachycardia associated with trasodone-amiodarone combination |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Priapism | Lipoprotein lipase precursor (P06858) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets |
| Toxicity And Inefficacy | CYP2D6 (P10635) | Toxicity in poor metabolisers@ inefficacy in ultrarapid metabolisers. [ ADR Type 3 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category